The body does not release growth hormone in a steady stream. It pulses it — rhythmic peaks and troughs across the day, with the largest pulse arriving at night during deep sleep. That pulsatile pattern is not a side effect; it is how the system is built to work. Downstream tissues respond differently to pulsatile delivery than to steady delivery, even when the total amount is the same.

This is the core reason a GHRH analog is a different intervention from replacing growth hormone directly. When you replace the hormone, you override the pulse. When you signal the pituitary with GHRH, the pituitary still drives the rhythm — you are just telling the manager to keep placing the orders in the cadence the system already uses. That is the manager-versus-assembly-line distinction, and it is not a small one in this lane of research.

Put another way: if pulsatile pattern did not matter, the entire rationale for studying a GHRH analog in age-advanced adults would collapse. You would just replace the hormone and be done. The fact that researchers spent a sustained-window study on the upstream approach tells you the pulse is treated as load-bearing, not cosmetic. That is the read on why this result matters.

The 1997 study was built to test whether the upstream GHRH signal still worked in age-advanced adults over an extended window — not whether replacing the hormone moved the marker. The design matters here. A study of replacement tells you the assembly line still runs when you stack parts on it. A study of upstream signaling tells you the manager still places orders when you talk to him. Those are different questions, and the second one is the one this study answered.

What the researchers observed was consistent with the upstream-mechanism story: the downstream marker moved, and the approach did not bypass the pituitary. That is the mechanism result. It is not the same as an outcome result — it tells you how the system was driven, not what driving it that way achieved over the long term.

It is also worth being clear about what the mechanism result does and does not let you conclude. It lets you say the pituitary in an age-advanced body can still hear the GHRH signal and respond to it over a sustained window. That is a real and useful piece of evidence. It does not let you say that preserving the pulse produces better outcomes than overriding it — that comparison would require a different study, and the 1997 work was not built to make it.

In plain terms: the studied approach talked to the system rather than replacing its output, and the system still listened in age-advanced adults. That is the kind of mechanism you want from an upstream signal — it tells you the lever is real and that it works the way the model says it works.

What it does not mean is that the upstream approach is always better than replacement, or that preserving the pulse reliably produces outcomes you would feel. The window was limited, the group was small, and the outcome comparison between upstream and replacement was not the question this study was built to answer.

The practical read is this: the pulsatile-GHRH result tells you sermorelin is an upstream lever, not a downstream substitute. That is worth a lot — it is the reason the rest of the sermorelin literature exists. What the data do not hand you is a long-term claim, a head-to-head comparison with replacement, or a protocol. The honest version keeps the mechanism result and the open outcome question visible together, and refuses to collapse one into the other.